Literature DB >> 12808483

Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications.

Gerian C Grönefeld1, Stefan H Hohnloser.   

Abstract

Atrial fibrillation and congestive heart failure are two distinct clinical entities that are responsible for significant morbidity and mortality in the Western world. Hypertension, coronary artery disease, and nonischemic cardiomyopathy represent the most prevalent underlying pathologies of both diseases, implying a coincidence of both in many patients. The prevalence of atrial fibrillation with a progressive degree of congestive heart failure is increasing, as judged by New York Heart Association functional class. Moreover, the presence of congestive heart failure has been identified as one of the most powerful independent predictors of atrial fibrillation, with a sixfold increase in relative risk of its development. On the other hand, atrial fibrillation can cause or significantly aggravate symptoms of congestive heart failure in previously asymptomatic or well-compensated patients. In some patients, symptomatic dilated cardiomyopathy may develop over time entirely due to atrial fibrillation with rapid ventricular rates. Upon restoration of sinus rhythm, this type of "tachymyopathy" has been shown to be often reversible. Recent investigations of the physiologic and structural changes of the atrial myocardium ("electrical and structural remodeling") have shown that neurohumoral activation, fibrosis, and apoptosis are demonstrable with both diseases. On the other hand, experimental data suggest that the substrates of atrial fibrillation in congestive heart failure are different from those of pure atrial tachycardia-related forms of atrial fibrillation. This review highlights the clinical and pathophysiologic similarities and differences of atrial fibrillation and congestive heart failure relevant to the understanding, treatment, and prevention of these diseases in the population at risk.

Entities:  

Mesh:

Year:  2003        PMID: 12808483     DOI: 10.1177/107424840300800203

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  11 in total

Review 1.  [Antiarrhythmic therapy with β-receptor antagonists].

Authors:  G C Grönefeld; D Bänsch
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-11-24

Review 2.  Atrial fibrillation and heart failure: cause or effect?

Authors:  Christina Luong; Marion E Barnes; Teresa S M Tsang
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 3.  Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure.

Authors:  Felix Hohendanner; F R Heinzel; F Blaschke; B M Pieske; W Haverkamp; H L Boldt; A S Parwani
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

Review 4.  Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.

Authors:  Christopher J Boos; Michael Nam; A J Camm
Journal:  Heart Fail Rev       Date:  2013-06-25       Impact factor: 4.214

5.  Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study.

Authors:  Agata Bielecka-Dabrowa; Jan Henryk Goch; Jacek Rysz; Marek Maciejewski; Ravi Desai; Wilbert S Aronow; Maciej Banach
Journal:  Lipids Health Dis       Date:  2010-02-23       Impact factor: 3.876

6.  Usefulness of the WCD in patients with suspected tachymyopathy.

Authors:  Julia W Erath; Mate Vamos; Alexander P Benz; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2017-10-09       Impact factor: 5.460

7.  Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial.

Authors:  Giovanni Luca Botto; Giuseppe Boriani; Stefano Favale; Maurizio Landolina; Giulio Molon; Claudio Tondo; Mauro Biffi; Giuseppe Grandinetti; Paolo De Filippo; Giovanni Raciti; Luigi Padeletti
Journal:  Trials       Date:  2011-02-15       Impact factor: 2.279

8.  Methods for the development and assessment of atrial fibrillation and heart failure dog models.

Authors:  Jon F Urban; Renee L Gerhart; Jason R Krzeszak; Corey R Leet; Linnea R Lentz; Carolyn B McClay
Journal:  J Geriatr Cardiol       Date:  2011-09       Impact factor: 3.327

9.  An altered expression of genes involved in the regulation of ion channels in atrial myocytes is correlated with the risk of atrial fibrillation in patients with heart failure.

Authors:  Mei Gao; Jiangrong Wang; Zhongsu Wang; Yong Zhang; Hui Sun; Xinxing Xie; Yinglong Hou
Journal:  Exp Ther Med       Date:  2013-02-05       Impact factor: 2.447

10.  Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety.

Authors:  Tsutomu Yoshikawa; Akiyasu Baba; Makoto Akaishi; Yasuhisa Wakabayashi; Toshiaki Monkawa; Masafumi Kitakaze; Tohru Izumi; Hitonobu Tomoike
Journal:  J Clin Apher       Date:  2016-01-23       Impact factor: 2.821

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.